To date much of the recent work on pathological angiogenesis has focused on inflammatory diseases, diabetes and cancer in particular. Hereditary hemorrhagic telangiectasia or Rendu-Osler-Weber disease provides an example of the genetic disorder of angiogenesis in which a multisystemic angiodysplasia is responsible for severe hemorrhage. The disease pathogenesis is partially explained by a defect in the TGF-β signaling system, although in more recent works a possible role of other vascular growth factors has been proposed. This paper provides a model of an aberrant angiogenesis in which multiple vascular growth factors could be involved in a diffuse angiodysplasia.

1.
Risau W: Mechanism of angiogenesis. Nature 1997;386:671–674.
2.
Folkman J: Angiogenesis in cancer, vascular rheumatoid and other disease. Nat Med 1995;1:27–31.
3.
Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757–1763.
4.
Pepper MS: Positive and negative regulation of angiogenesis: From cell biology to the clinic. Vasc Med 1997;1:253–266.
5.
Guttmacher AE, Marchuk DA, White RI Jr: Hereditary hemorrhagic telangiectasia. N Engl J Med 1995;333:918–924.
6.
Plauchu H, de Chadarevian JP, Bideau A, Robert JM: Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989;32:291–297.
7.
McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J: Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345–351.
8.
Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, Guttmacher AE, Jackson CE, Attisano L, Kucherlapati R, Porteous ME, Marchuk DA: Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996;13:189–195.
9.
Piantanida M, Buscarini E, Dellavecchia C, Minelli A, Rossi A, Buscarini L, Danesino C: Hereditary haemorrhagic telangiectasia with extensive liver involvement is not caused by either HHT1 or HHT2. J Med Genet 1996;33:441–443.
10.
Pepper MS: Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 1997;8:21–43.
11.
Shovlin CL, Scott J: Inherited diseases of the vasculature. Annu Rev Physiol 1996;58:483–507.
12.
Bellon T, Corbi A, Lastres P, Cales C, Cebrian M, Vera S, Cheifetz S, Massague J, Letarte M, Bernabeu C: Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 1993;23:2340–2345.
13.
Thorpe PE, Burrows FJ: Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat 1995;36:237–251.
14.
Wang JM, Kumar S, van Agthoven A, Kumar P, Pye D, Hunter RD: Irradiation induces up-regulation of E9 protein (CD105) in human vascular endothelial cells. Int J Cancer 1995;62:791–796.
15.
Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD: A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 1993;54:363–370.
16.
Barbara NP, Wrana JL, Letarte M: Endoglin is an accessor protein that interacts with the signaling receptor complex of multiple members of transforming growth factor-β superfamily. J Biol Chem 1999;274:584–594.
17.
Marchuk DA: Genetic abnormalities in hereditary hemorrhagic telangiectasia. Curr Opin Hematol 1998;5:332–338.
18.
Pece N, Vera S, Cymerman U, White RI Jr, Wrana JL, Letarte M: Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative. J Clin Invest 1997;100:2568–2579.
19.
Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB, Wendel DP: Defective angiogenesis in mice lacking endoglin. Science 1999;284:1534–1537.
20.
Bourdeau A, Dumont DJ, Letarte M: A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 1999;104:1343–1351.
21.
Shovlin CL, Hughes JM, Scott J, Seidman CE, Seidman JG: Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet 1997;61:68–79.
22.
Attisano L, Carcamo J, Ventura F, Weis FM, Massague J, Wrana JL: Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993;75:671–680.
23.
ten Dijke P, Ichijo H, Franzen P, Schulz P, Saras J, Toyoshima H, Heldin CH, Miyazono K: Activin receptor-like kinases: A novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. Oncogene 1994;8:2879–2887.
24.
Ryden M, Imamura T, Jornval H, Belluardo N, Nevue I, Trupp M, Okadome T, ten Dijke P, Ibanez CF: A novel type I receptor serine-threonine kinase predominantly expressed in the adult central nervous system. J Biol Chem 1996;271:30603–30609.
25.
Lux A, Attisano L, Marchuk DA: Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1. J Biol Chem 1999;274:9984–9992.
26.
Kretzschmar M, Massagué J: SMADs: Mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev 1998;8:103–111.
27.
Bassing CH, Yingling JM, Howe DJ, Wang T, He WW, Gustafson ML, Shah P, Donahoe PK, Wang XF: A transforming growth factor beta type I receptor that signals to activate gene expression. Science 1994;263:87–89.
28.
Panchenko MP, Williams MC, Brody JS, Yu Q: Type I receptor serine-threonine kinase preferentially expressed in pulmonary blood vessels. Am J Physiol 1996;270:L547–L558.
29.
Roelen B, van Rooijen M, Mummery CL: Expression of ALK-1, a type 1 serine/threonine kinase receptor, coincides with sites of vasculogenesis and angiogenesis in early mouse development. Dev Dyn 1997;209:418–430.
30.
Dickson K, Philip A, Warshawsky H, O’Connor-McCourt M, Bergeron JJ: Specific binding of endocrine transforming growth factor-beta 1 to vascular endothelium. J Clin Invest 1995;95:2539–2554.
31.
Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, Li E: Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 2000;97:2626–2631.
32.
Folkman J, D’Amore PA: Blood vessel formation: What is its molecular basis? Cell 1996;87:1153–1155.
33.
Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ: Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knockout mice. Development 1995;121:1845–1854.
34.
Proetzel G, Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN, Ding J, Ferguson MW, Doetschman T: Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 1995;11:409–414.
35.
Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, Groffen J: Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 1995;11:415–421.
36.
Shovlin C, Letarte M: Hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations: Issues in clinical management and review of pathogenic mechanisms. Thorax 1999;54:714–729.
37.
Azuma H: Genetic and molecular pathogenesis of hereditary hemorrhagic telangiectasia. J Med Invest 2000;47:81–90.
38.
Pepper MS, Vassalli JD, Orci L, Montesano R: Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp Cell Res 1993;204:356–363.
39.
Lux A, Attisano L, Marchuk DA: Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1. J Biol Chem 1999;274:9984–9992.
40.
Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994;368:419–424.
41.
Jacobson BS: Hereditary hemorrhagic telangiectasia: A model for blood vessel growth and enlargement. Am J Pathol 2000;156:737–742.
42.
Braverman IM, Keh A, Jacobson BS: Ultrastructure and three-dimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia. J Invest Dermatol 1990;95:422–427.
43.
Sonstein WJ, Kader A, Michelsen WJ, Llena JF, Hirano A, Casper D: Expression of vascular endothelial growth factor in pediatric and adult cerebral arteriovenous malformations: An immunocytochemical study. J Neurosurg 1996;85:838–845.
44.
Hatva E, Jaaskelainen J, Hirvonen H, Alitalo K, Haltia M: Tie endothelial cell-specific receptor tyrosine kinase is upregulated in the vasculature of arteriovenous malformations. J Neuropathol Exp Neurol 1996;55:1124–1133.
45.
Puri MC, Rossant J, Alitalo K, Bernstein A, Partanen J: The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J 1995;14:5884–5891.
46.
Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171–1180.
47.
Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y: Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995;376:70–74.
48.
Bourdeau A, Cymerman U, Paquet ME, Meschino W, McKinnon WC, Guttmacher AE, Becker L, Letarte M: Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1. Am J Pathol 2000;156:911–923.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.